Johnson & Johnson

Health Care Pharmaceuticals New Brunswick, New Jersey Last filing Feb 11, 2026 · FY2025

                    Revenue
                    FY2025
                
$94.2B
                    
                    +6.0%
                    
                    Net income
                    FY2025
                
$26.8B
                    
                    +90.6%
                    
                    Total assets
                    FY2024
                
$180.1B
                    
                    -3.9%
                    
                    Operating cash flow
                    FY2024
                
$14.1B
                    
                    -21.6%

Balance Sheet

Assets, liabilities, and equity

11 accounts · 5 years

Total assets $180.1B

Total liabilities $108.6B

Shareholders equity $180.1B

Account	2025	2024	2023	2022	2021
Statement
BS Assets Short Term Invest	$0	—	$4.5B	—	—
BS Assets Accts Receivable	$0	—	$14.9B	—	—
BS Assets Inventory	$0	—	$11.2B	—	—
BS Assets PPE	$0	—	$19.9B	—	—
BS Assets Goodwill	$3.5B	—	$36.6B	—	—
BS Liab Accrued Liab	$0	—	$10.2B	—	—
BS Liab Other Noncurrent	$0	—	$13.4B	—	—
BS Equity Preferred Stock	$0	—	$0	—	—
BS Equity Common Stock	$0	—	$3.1B	—	—
BS Equity Treasury Stock	$6.0B	—	$75.7B	—	—
BS Equity AOCI	$0	—	$-12.5B	—	—

Income Statement

Revenue, expense, and profitability

20 accounts · 5 years

Revenue $94.2B

Operating income $26.8B

Net income $26.8B

Account	2025	2024	2023	2022	2021
Statement
IS Revenue Total	$94.2B	—	$85.2B	—	—
IS Expense COGS	$30.3B	—	$26.6B	—	—
IS Expense Rn D	$109.0M	—	$483.0M	—	—
IS Expense SGA	$23.7B	—	$21.5B	—	—
IS Expense DA	$7.5B	—	$7.5B	—	—
IS Expense SBC	$1.4B	—	$1.2B	—	—
IS Expense Restructuring	$228.0M	—	$489.0M	—	—
IS Gross Profit	$63.9B	—	$58.6B	—	—
IS Operating Income	$26.8B	—	$13.3B	—	—
IS Interest Income	$1.1B	—	$1.3B	—	—
IS Interest Expense	$971.0M	—	$772.0M	—	—
IS Other Nonop Inc Exp	$7.2B	—	$-6.6B	—	—
IS Pre Tax Income	$32.6B	—	$15.1B	—	—
IS Tax Expense	$5.8B	—	$1.7B	—	—
IS net Income	$26.8B	—	$35.2B	—	—
IS Comprehensive Income	$-3.2B	—	$-4.7B	—	—
IS EPS Basic	$11	—	$14	—	—
IS EPS Diluted	$11	—	$14	—	—
IS Shares Basic	$2.4B	—	$2.5B	—	—
IS Shares Diluted	$2.4B	—	$2.6B	—	—

Cash Flow Statement

Operating, investing, and financing flows

20 accounts · 5 years

Operating cash flow $14.1B

Investing cash flow $4.4B

Financing cash flow $6.7B

Account	2025	2024	2023	2022	2021
Statement
CF Ops net Income	$26.8B	—	$35.2B	—	—
CF Ops DA	$7.5B	—	$7.5B	—	—
CF Ops SBC	$1.4B	—	$1.2B	—	—
CF Ops Deferred Tax	$1.5B	—	$-4.2B	—	—
CF Ops Working Capital	$3.2B	—	$1.9B	—	—
CF Ops Other	$-5.7B	—	$5.6B	—	—
CF Ops net Cash	$24.5B	—	$22.8B	—	—
CF Inv Capex	$4.8B	—	$4.5B	—	—
CF Inv Acquisitions	$17.5B	—	$0	—	—
CF Inv Purchase Investments	$920.0M	—	$10.9B	—	—
CF Inv Other	$162.0M	—	$-12.0M	—	—
CF Inv net Cash	$-23.6B	—	$878.0M	—	—
CF Fin Debt Issuance	$9.1B	—	$0	—	—
CF Fin Debt Repayment	$1.8B	—	$1.6B	—	—
CF Fin Share Repurchases	$6.0B	—	$5.1B	—	—
CF Fin Dividends	$12.4B	—	$11.8B	—	—
CF Fin Other	$-34.0M	—	$-269.0M	—	—
CF Fin net Cash	$-5.5B	—	$-15.8B	—	—
CF FX Effect	$201.0M	—	$-112.0M	—	—
CF net Change	$-4.4B	—	$7.7B	—	—

Stock Data

One-year price and volume history

Data not loaded

Price data unavailable

Stock price history for JNJ has not been loaded yet.

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

One-year price and volume history

Price data unavailable

Recent price history